The international medical device conference held in Orlando this year was different from other clinical conferences we attend in that it was much smaller and was concentrated around a broader range of topics covering the entire spectrum of medical devices. The talks were focused on innovations in the medical device industry. I particularly enjoyed Dr. Amit Mishra’s lecture—he spoke about his device that enabled the inexpensive repair of apical muscular ventricular septal defects in children. His device was fashioned in his lab out of polytetrafluoroethylene material commercially sold as Gortex and was several thousands of dollars cheaper than the device manufactured by Medtronic for the same purpose. Another interesting new innovation covered in the conference was the Mirena intrauterine device. This device is increasingly gaining traction in the US as a means to regulate heavy menstrual bleeding. However, now scrupulous physicians are increasingly using it in India as well as a means to prevent hysterectomies. It currently constitutes a small but rapidly growing market in India.

In my talk, I covered some of the dramatic innovations expected to hit the US diabetes market in the future. These innovations are key to improving the lives of the millions of diabetics who live in the US. Among these was the artificial pancreas system currently in development by Medtronic, which would make diabetes management completely automated for type 1 diabetics. After this, I covered the ITCA 650 drug delivery system, which would help make diabetes management more automated for type 2 diabetics. This implant would be placed subdermally in the abdomen of the patient where it would release a continuous supply of the GLP-1 exenatide. This could change the current treatment algorithm for type 2 diabetics by making it a new third-line option after lifestyle measures and oral medications. Finally, I talked about stem cell research, which is currently in very early stages of testing and development. While this technology has the potential to substantially alter the treatment algorithm for both type 1 and type 2 diabetics and even eradicate the disease, it also faces substantial hurdles before it can become a mainstream option; the biggest among them is the chance of rejection by the host.

This conference was particularly enjoyable since I had the chance to present my research and DRG’s capabilities to the diverse audience consisting of physicians and industry experts. I do hope that many such opportunities will arise in the future for all our analysts to showcase their formidable expertise in their fields of research.

Pivoting a product launch during the pandemic

View Now